Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:391-393
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bahlis Nizar Jacques¹,Tomasson Michael H.²,Mohty Mohamad³,Niesvizky Ruben⁴,Nooka Ajay K.⁵,Manier Salomon⁶,Maisel Christopher⁷,Jethava Yogesh⁸,Martinez-Lopez Joaquin⁹,Prince H Miles¹⁰,Arnulf Bertrand¹¹,Rodriguez Otero Paula¹²,Koehne Guenther¹³,Touzeau Cyrille¹⁴,Raje Noopur¹⁵,Iida Shinsuke¹⁶,Raab Marc-Steffen¹⁷,Leip Eric¹⁸,Sullivan Sharon¹⁹,Conte Umberto²⁰,Viqueira Andrea²¹,Lesokhin Alexander M²²

Affiliation:

1. 1Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada

2. 2Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA

3. 3Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France

4. 4Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY

5. 5Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

6. 6CHU de Lille, Lille, France

7. 7Baylor University Medical Center, Dallas, TX

8. 8Indiana Blood & Marrow Transplantation, Indianapolis, IN

9. 9Hospital Universitario 12 de Octubre, Madrid, Spain

10. 10Epworth Healthcare, Melbourne, Australia

11. 11Hôpital Saint-Louis, Paris, France

12. 12Clinica Universidad de Navarra, Madrid, Spain

13. 13Blood and Marrow Transplant Program, Miami Cancer Institute, Baptist Health, Miami, FL

14. 14Centre Hospitalier Universitaire (CHU) de Nantes, INSERM, Université de Nantes, Nantes, France

15. 15Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

16. 16Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

17. 17Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany

18. 18Pfizer Inc., Cambridge, MA

19. 19Pfizer Inc, Cambridge, MA

20. 20Pfizer Inc, New York, NY

21. 21Pfizer SLU, Madrid, Spain

22. 22Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management;Cancers;2024-06-19

2. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?;Expert Review of Hematology;2024-05-21

3. Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis;Clinical Hematology International;2024-05-06

4. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma;Expert Opinion on Biological Therapy;2024-05-03

5. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma;The Lancet Oncology;2024-05